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Abstract
Background: Despite the recognition of the importance of diagnosing dysglycaemia in patients with acute coronary
syndrome (ACS) there remains a lack of consensus on the best screening modality. Our primary aims were to determine
the prevalence of undiagnosed dysglycaemia and to compare the OGTT and HbA1c criteria for diagnosis of T2DM in
patients admitted to hospital with ACS at baseline and at 3-months. We also aimed to investigate the role of a screening
algorithm and a predictor score to define glucose tolerance in this population.
Methods: A prospective study in which patients admitted with ACS to two UK teaching hospitals were assessed at
baseline and 3 months follow-up.
Results: The prevalence of diabetes at baseline was 20% and 16% based on OGTT and HbA1c criteria respectively.
Forty three (43) % of the patients with T2DM based on OGTT would have been missed by the HbA1c criteria at baseline.
Our screening algorithm identified 87% of patients with T2DM diagnosed with OGTT. Diabetes Predictor score had better
sensitivity (>80%) and negative predictive value (>90%) compared to HbA1c criteria. Two thirds of participants with IGS
and a third with T2DM changed their glycaemic status at 3 months.
Conclusions: Only 48% of the patients admitted with ACS had normo-glycaemia based on OGTT. OGTT and HbA1c
identified two different populations of patients with dysglycaemia with the HbA1c criteria missing almost half the patients
with T2DM based on OGTT. Compared to HbA1c criteria our diabetes algorithm and diabetes predictor score had a
better correlation with OGTT criteria.
Background
Acute coronary syndrome (ACS) comprises a wide
spectrum including non-ST segment elevation myocardial
infarction (NSTEMI) and ST segment elevation MI
(STEMI) [1, 2] and affects approximately 7 million people
worldwide [2, 3]. Diabetes mellitus is a major risk factor
for cardiovascular disease [4]. Dysglycaemia is associated
with increased mortality and morbidity in patient with
ACS as well as poor immediate outcomes [5–11].
Hospitalized patients with ACS have a high incidence
of impaired glycaemic status (IGS) and Type 2
diabetes (T2DM) [10–15] with, 33% having impaired
glucose tolerance (IGT) and 33% having T2DM [10].
Although the magnitude of this problem is increas-
ingly being appreciated [10–15], the best mode for
screening is unclear. Some reports indicate using an
oral glucose tolerance test (OGTT) at the time of
discharge from hospital in patients with ACS is a reli-
able method in predicting glycaemic status at 3 and
12 months [10]. However, these data also indicate an
uncertainly of outcome since less than 50% of patients di-
agnosed with diabetes at the time of discharge still met
the criteria at 12 months [10]. It is also clear from studies
such as UKPDS and DCCT that early detection of dia-
betes prevents the development of long term complica-
tions [16–18].
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The European Association for the study of Diabetes
(EASD) recommends the use of an OGTT to investigate
glycaemic abnormalities in patients with CVD without a
known diagnosis of diabetes [19]. In contrast, this
approach is not supported by the American Heart
Association Diabetes Committee of the Council on
Nutrition, Physical Activity and Metabolism [20]. This
partly reflects the scarcity of conclusive evidence indicat-
ing that early intensive glycemic control improves
cardiovascular outcomes. It is also unclear whether the
acute dysglycaemia is a cause or effect of the myocardial
ischemia and whether it justifies treatment per se or
whether it should be viewed as a transient stress marker
[21, 22]. Moreover, the complexity of performing an
OGTT is also a factor: data from Holland suggest that
76% of cardiologists do not check an HbA1c in patients
with ACS before discharge [23], making it unlikely
that a more impractical test like OGTT would be
used more frequently.
Until recently the diagnosis of diabetes was based on
OGTT criteria [24]. However, the need for a simple and
reliable screening tool has long been recognised and an
International Expert Committee comprising the EASD,
American Diabetes Association (ADA) and International
Diabetes Federation (IDF) in 2009 recommended the use
of an HbA1c cut-off of 6.5% (48 mmol/mol) for the
diagnosis of diabetes provided the methodology was stan-
dardized and subjected to quality assurance protocols
[25]. These criteria have now been adopted by the WHO.
We have developed a simple T2DM screening
algorithm based on the FPG and HbA1c in the general
public [26]. This was originally designed to limit the
number of subjects requiring an OGTT in a group of
patients referred due to abnormal impaired fasting
glucose (IFG). The FPG identified 36% of patients with
diabetes mellitus while OGTT identified a further 12%.
The derived algorithm, [HbA1c ≥ 6.0% (42 mmol/mol)
with FPG < 7.0 mmol/l] was utilized to identify patients
requiring an OGTT to diagnose diabetes. When applied
to the UK validation cohort, sensitivity was 97% and spe-
cificity 100%. Use of the algorithm would have reduced
the number of OGTTs performed in the UK validation
cohort by 33% and in the Australian cohort by 66%.
Hence this could simplify procedures for diagnosis of
diabetes, but validation was required in other patient
groups [26]. Our primary aims were:
1. To determine prevalence of undiagnosed diabetes
and impaired glycaemic state (according to OGTT
criteria) in patients admitted with ACS.
2. To compare the OGTT and HbA1c criteria for
diagnosis of T2DM in patients admitted to
hospital with ACS at baseline and at 3-month
follow up.
3. To investigate the role of simple and reproducible
screening methods such as diabetes predictor score
and screening algorithm to accurately define glucose
tolerance in patients admitted with ACS.
Methods
We conducted a cross-sectional and prospective study of
adult patients who were admitted with ACS (STEMI and
NSTEMI) to two secondary care inner-city hospitals in
Birmingham UK between 2008 and 2010. One hundred
and eighteen (118) Patients aged 18-90 years and not--
known to have diabetes prior to admission were
recruited. We excluded patients known to have diabetes
(from past medical and medication history) or non-
cardiac chest pain based on cardiac assessment. The
patients were approached by a member of the research
team (either a research nurse or a clinician) within 3 days
of admission and baseline data and blood samples were
obtained within 7 days of the cardiac event. The study
was approved by the Birmingham, East, North and
Solihull Research Ethics Committee (reference number
08/H1206/5) and all patients were consented as per the
ethical approval.
Assessments
Data collected during one-to-one interview and from
electronic records included age, gender, ethnicity (deter-
mined in accordance with the UK decennial census by the
study participants), medications, past medical history,
family history, smoking history, history of hypertension
and dyslipidaemia. Nature of the cardiac event, treatment
received and outcome of underlying cardiac condition
were also recorded. Other data included height, weight,
body mass index (BMI), HbA1c, lipid profile, and blood
pressure (BP). BP was measured by an automated Omron
HEM-907 device (Omron Healthcare, Netherlands) whilst
patient was seated with left arm resting horizontally. The
average of 2 measurements taken at least 10 min apart
after 30 min of rest was used.
Blood sampling
Fasting plasma and serum samples were collected and
were stored at -80 oC following centrifugation. Glucose
and HbA1c as well as basic biochemistry were carried
out on fresh samples.
Glucose
Glucose was measured using a hexokinase kit (Cat. No.
11876899216) and C.f.a.s. calibrator for automated
systems (Cat. No. 10759350190) on a Roche Modular
platform (Roche Diagnostics, E Sussex, UK) with coeffi-
cients of variance across the range of <2%.
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OGTT
OGTTs were performed at admission (within 7 days)
and 3 months from baseline. Patients were requested to
fast from the previous evening for 10 h and bloods
collected the next morning. Plasma glucose and HbA1c
were measured on venous blood. For the 75 g OGTT,
patient was asked to drink 113 mL glucose polymer
drink, Polycal, (Nutricia Clinical Care, Wiltshire, UK)
over a period of 5 min. A further venous blood sample
was taken after 2 h for plasma glucose measurement.
Diagnosis of diabetes was based on OGTT criteria [24].
All patients received standard life-style advice given to post
MI patients. Patients with HbA1c > 7.5% (58 mmol/mol) at
baseline received glucose lowering treatment and did not
have follow-up OGTT (n = 8/23, 35%).
HbA1c
‘DCCT aligned’ HbA1c was reported from an ion
exchange, high performance, liquid chromatography
analyser, TOSOH G7 A1c Variant Mode (Tosoh
Bioscience Ltd, Worcs, UK) that detects haemoglobin
variants. A reference interval of <6% (42 mmol/mol)
HbA1c was quoted by the manufacturer. HbA1c was
not reported in patients with variant haemoglobins.
There was one patient in our study identified with
variant Hb.
Screening algorithm
Our team has developed and published a T2DM screen-
ing algorithm based on FPG and HbA1c (Figure 1) [26]. It
was derived from oral glucose tolerance test (OGTT) capil-
lary samples in 500 consecutive UK patients referred with
IFG and validated in 500 UK patients as well as venous
specimens in 1175 unselected Australian patients [26].
Statistical analysis
Based on previous publications [10] we expected a 33%
prevalence of T2DM in our cohort. Using our screening
algorithm [26] in order to achieve sensitivity of 97%
(95% confidence interval 84-100%) and specificity of 94%
(95% confidence interval 85-98%) we needed a sample
size of 100 participants. Allowing for 10% drop outs we
aimed to recruit 110 patients.
Data analyses were performed using SPSS 15.0 soft-
ware (SPSS Inc, Chicago, IL). Data are presented as
mean ± SD or frequencies. Independent continuous
variables were compared using the Student t test.
Categorical variables were compared using the Chi-
square test. Correlations between continuous variables
were performed using the Pearson or Spearman tests.
Differences between independent groups were assessed
by analysis of variance (ANOVA). If the homogeneity of
variance assumption of ANOVA was violated, the Welch
statistics were used to calculate the P values.
To assess the relationship between continuous and/or
categorical variables and dichotomous outcomes mul-
tiple logistic regressions (forced entry method) was used.
Variables included in the regression models were based
on known outcome-related risk factors. We assessed
multicolinearity in both multiple linear and logistic
regression models using simple correlations between
variables plus the tolerance values, and the condition in-
dices. No tolerance values were < 0.1 and no variables
had strong correlations (r > 0.8). In multiple linear
regression models, the residuals were examined. In all
the models presented, residuals followed a normal distri-
bution with uniform variance and there was no relation-
ship between the residual and predictor of interest. Data
distribution was assessed using histograms and the
Shapiro-Wilk test. A p value < 0.05 was considered sig-
nificant unless stated otherwise.
Results
One hundred and ninety eight (198) patients without
diabetes were approached, of which 118 were consented.
Participants’ clinical characteristics are summarised in
Table 1. The study population was largely of middle age
White men (81 male and 80% White Caucasian)
(Table 1). Diagnoses of STEMI and NSTEMI were estab-
lished in 43 and 57%, of the cohort respectively.
Figure 1 The screening algorithm
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Prevalence of diabetes mellitus and impaired glycemia
Baseline assessments
Glycemic status based upon WHO criteria At base-
line, 48% (57/118) of participants had normal glucose
tolerance (NGT), 32% (38/118) impaired glycaemic status
(IGS) (which included 3% IFG (3/118), 25% IGT (30/118)
and 4% IFG + IGT (5/118)) and 20% (23/118) met the
criteria for T2DM.
Patients with T2DM were older and more obese
(Table 2).
Glycaemic status based upon HBA1C criteria
At baseline, the prevalence of diabetes based upon an
HbA1c >6.5% was 16%. Similar to the WHO criteria,
patients with T2DM were older (age 60 + 11 and 67 + 11
for NGT vs. T2DM, p = 0.05) and more obese (BMI
28 + 5 vs. 31 + 6 for normal vs. T2DM, p = 0.04)
compared to patients without T2DM.
Glycaemic status: WHO vs. HBA1C (Figure 2a)
All patients classified as NGT on WHO criteria also
had HbA1c ≤ 6.5% (48 mmol/mol) (Figure 2a). However
43% (n = 10/23) of the participants classified as having
T2DM on the OGTT criteria would have been classified
as patients without diabetes based on the HbA1c cri-
teria. Out of 37 patients classified as IGS on the OGTT
criteria 31 (84%) were classified as normal based on the
HbA1c criteria.
3 month assessments
Glycaemic status at 3 months
The glycaemic status was reclassified at 3 months
following discharge from hospital Data were available at
this time point for 101 participants (14 drop outs, 3
died). All three participants who died had abnormal
glycemia (2 IGT, 1 DM). At 3 months, 54% (55/101) of
participants had NGT, 25% (25/101) IGS [9% (9/101)
IFG, 11% (11/101) IGT and 5% (5/101) IFG + IGT)] and
21% (21/101) T2DM.
At the 3 months visit patients with T2DM were older
and more obese than those with NGT (Table 2).
Comparing the glycaemic status based on the HbA1c
and the OGTT criteria at 3 months showed that HBA1C
would have incorrectly classified as normal 7 (33%)
subjects with T2DM based on the 3 months OGTT
(Figure 2b). Only one of the subjects classified as normal
Table 1 Clinical and metabolic parameters of study participants
Variables Mean S.D Median IQR Min Max
Age (Years) (n = 118) 61 11.9 61 53-71 31 90
BMI (kg/m²) (n = 106) 28 5.1 28 25-32 17 47
Baseline FPG (mmol/L) (n = 118) 5.7 1.2 5.4 5.0-6.0 4.3 13.1
Baseline 2 hr PG (mmol/L) (n = 118) 8.5 3.7 7.7 5.9-9.9 2.4 23.5
Baseline HbA1c (%)a mmol/mol (n = 117) 6.1 (43) 0.84 5.9 5.7-6.2 4.8 (29) 10.6 (92)
Follow up FPG (n = 92)b 5.7 0.99 5.6 5.2 – 6.1 2.1 10.4
Follow up 2 hr PG (n = 91)b 6.8 2.8 5.9 5-8.5 2.4 15.4
Follow up HbA1c (n = 96) 6.2 0.8 5.9 5.7-6.3 5.1 10.8
Systolic BP (mmHg) (n = 110) 126 20.5 122 110-138 91 192
Diastolic BP (mmHg) (n = 110) 74 12 73 65-81 47 115
Fructosamine (μmol/L) (n = 86) 213 28.7 210 196-228.2 169 401
The total study population was 118, 8 patients has missing data for BP and 12 patients has missing data for BMI
aHbA1c was not reported in one participant due to the presence of variant Haemoglobin
bFor the follow up OGTT we had data for 92 patients. Out of 118 who had baseline data, 14 were lost to follow up, 3 deceased, 8 did not have follow up OGTT
because they were initiated on treatment for T2DM, and 1 did not have follow up OGTT due to HbA1c variant
Table 2 Associations of means of basic parameters with
background and 3 month glycaemic status
NGT IGS T2DM P value
Sex (Male) 47 30 19 0.89
Age (Years) 57+ 11 64+ 10 67+ 12 0.001
BMI (kg/m²) 27 + 4 29+ 4 31 + 7 0.02
Fructosamine 207 + 17 208+ 22 236 + 47 0.001
Ethnicity
Afrocaribbean 3 2 0 0.75
Asian 9 5 5
Caucasian 45 31 18
Sex (Male) 41 22 17 0.38
Age (Years) 59+ 11 61+ 10 66+ 12 0.08
BMI (kg/m²) 28 + 5 28+ 5 32 + 5 0.008
Fructosamine 207 + 18 213+ 19 232 + 49 0.01
Ethnicity
Afrocaribbean 2 1 1 0.55
Asian 7 7 3
Caucasian 46 17 17
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on the OGTT criteria at 3 months had T2DM based on
the initial HbA1c (HbA1c criteria). Participants classified
as having IGS at 3 months were mostly normal (88%) on
the HbA1c criteria with only 3 (12%) having T2DM.
Diabetes predictor score (DPS)
The screening algorithm had been designed to reduce the
number of referrals for OGTT. We wanted to look at an
algorithm which would perform well against WHO cri-
teria as gold standard when used to detect T2DM. There-
fore we examined clinical parameters that differed
between patients with and without diabetes including age,
BMI, sex, ethnicity, FPG, HbA1c, and nature of the car-
diac event. Age, BMI, HbA1c, FPG differed between pa-
tients with and without diabetes and using logistic
regression significant predictors of diabetes status were
age, FPG and HbA1c (Table 3). The equation we designed
based on the regression co-efficients was as follows:
Diabetes predictor score = (0.1 * Age) + (1.7 * FPG) + (1.6 *
HbA1c)
At baseline, compared to OGTT as the gold standard to
detect T2DM the DPS had an AUC of 90% (p < 0.001)
a
b
Figure 2 a Glycaemic status in the study population based on the WHO (x-axis) and HbA1c criteria (y-axis). b Glycaemic status in the study
population based on the WHO criteria (Y axis) at 3 months and HbA1c (X axis) criteria at baseline
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while A1C had an AUC of 82% (Figure 3). Using a cut-
off at 26.32 achieved sensitivity of 83% with specificity of
87%. Positive and negative predictive values were 61 and
95% respectively. In comparison HBA1C criteria was as-
sociated with sensitivity of 57% and specificity of 94%.
Positive and negative predictive values were 68% and
90% respectively.
At the 3 month visit, DPS had significant correlation
with the WHO criteria, with an AUC of 89% (p < 0.001)
while A1C had an AUC of 84% (Figure 3). Using a cut-
off at 26.32 achieved sensitivity of 81 and specificity of
89%. Positive and negative predictive values were 66 and
95% respectively. In comparison HBA1C criteria was as-
sociated with sensitivity of 67% and specificity of 95%.
Positive and negative predictive values were 78 and 91%
respectively.
The utility of the screening algorithm
By applying our screening algorithm, 20 out of 23 patients
(87%) with T2DM would have been referred for an OGTT
(i.e. 3 patients (13%) with T2DM based on OGTT would
have been missed by the screening algorithm).
On the contrary, 42 out of 57 patients with normal
OGTT results (74%) would not have been referred. In
addition the screening algorithm would have detected
56% of the patients with IGT (These patients would have
been referred for OGTT).
At 3 months, the use of the screening algorithm would
have only missed 3 patients (14.3%) with T2DM. 18 out
of 21 patients with DM would have been referred for an
OGTT. In contrast, 36 out of 55 patients with normal
OGTT results (65.5%) would not have been referred.
Conclusions
In this study we have found that 51% of the patients ad-
mitted with ACS have either T2DM or IGS at baseline.
However, two thirds of patients with T2DM or IGS at
baseline changed their glycaemic status at 3 months.
The HbA1C criteria would have miss-classified 43% of
patients with T2DM at baseline on OGTT as NGT.
Considering that OGTT may still be considered the
“gold-standard” in this setting but is costly and time
consuming, our screening algorithm managed to reduce
the number of patients requiring OGTT significantly
and only missed 13% of people with T2DM. Our
diabetes predictor score had a good performance com-
pared to OGTT-criteria at baseline and follow-up to
diagnose T2DM.
The OGTT and HbA1c diagnostic criteria gave a
different prevalence of diabetes in our cohort). By using
the two different criteria we are identifying different
cohort of patients with diabetes. Although the perform-
ance of the HbA1c criteria is better at 3 months, there
are still differences in the classification of patients. The
reason for the improved performance of the HbA1c
criteria at 3 months may be due to HbA1c reflecting
Table 3 Logistic regression to identify statistically significant
predictors of glycaemic status (diabetes vs. else) in order to
compute the Diabetes Predictor Score
Variable Regression
co-efficient
Odds ratio Confidence
interval
p value
BMI 0.05 1.0 0.91-1.23 0.49
Age 0.1 1.1 1.03-1.19 0.007
HbA1c 1.6 4.8 1.19-19.1 0.03
FPG 1.7 5.4 1.89-15.8 0.002
Nagelkerke R2 0.59
Figure 3 ROC curve analysis for the performance of the diabetes predictor score and HbA1c compared to WHO criteria to diagnose T2DM. A: at
baseline, B: at 3 month
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longer term glycemic status compared to OGTT and its
better reproducibility. In addition to the clinical implica-
tions of inconsistencies in the diagnosis of T2DM in
patients with ACS, there are important considerations
with regards to the diagnosis of IGS. The detection of
IGS has important implications for subsequent cardio-
vascular morbidity and mortality [10–15]. Patients with
IGS are also known to progress to T2DM with studies
suggesting an incidence of around 57.2 per 1000 patient
years [27]. Other studies have suggested similar findings
with incidence ranging from 35 to 58 per 1000 patient-
years depending on ethnicity [28, 29]. IGT has also been
known to be associated with cardiovascular mortality.
Whitehall study suggested an increase in cardiovascular
mortality by double in patients with abnormal OGTT
results (2 h PG > 5.3 mmol/l) vs. normal Identification of
IGT may afford opportunities for therapeutic life style
modification or pharmacological interventions such as
metformin which may slow the progression to T2DM
[27] and impact cardiovascular outcomes In this report,
all 3 participants who died had abnormal glycaemic
status with two having IGS at baseline all of whom
would have been classified as normal based upon the
HbA1c criteria.
Our screening algorithm correlated well with the
OGTT criteria. Overall, its use would lead to a reduction
in the OGTTs. Moreover, an advantage compared to the
use of an HbA1c measurements alone, use of the screen-
ing algorithm identifies at 50% of the participants with
IGS. In comparison, the HbA1c criteria can detect less
than 20% of IGS subjects and would label them all as
having T2DM (Figure 2b).
The screening algorithm was originally designed to
reduce the number of OGTTs required rather than to
define glucose tolerance. We therefore evaluated a modi-
fied algorithm which performed better when compared
to the OGTT criteria. Our DPS performed better than
the HbA1c criteria in terms of sensitivity and NPV.
However compared to the OGTT criteria, its positive
predictive values were lower suggesting that it would
classify some patients incorrectly as having T2DM there-
fore we propose that DPS is used to “exclude” diabetes.
Our study does have some limitations. The prevalence
of diabetes in our study was lower compared to previous
studies [10] which could impact some of our subsequent
analysis. Our cohort of patients comprised 80% white
Caucasians and so it is difficult to know whether these
data apply equally to other ethnic groups. The follow up
period of 3 months is relatively short and so may not
predict longer term glycaemic status.
In patients with ACS, the use of differing diagnostic
criteria has a significant impact on the glycaemic classifi-
cation of patients which may have importance for longer
term cardiovascular outcomes. Glycaemic classification
during hospitalization, may not accurately predict the
subsequent diabetes status particular in patients with
IGS. The use of a screening algorithm and predictor
score appears to be a better predictor of glycemic status
compared to the HbA1c criteria when using OGTT
criteria as a standard and may serve as useful tools for
the assessment of hospitalized patients and reduce the
number of OGTTs required. The utility of the screening
algorithm and DPS in predicting glycaemic status and
their impact on the need for OGTT need to be exam-
ined in larger cohorts with longer follow up duration
(12-24 months).
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